Testing a drug given two ways for cancer spread to the lining of the brain
Official title: Combined Intrathecal and Systemic Therapy With Trastuzumab Rezetecan for Leptomeningeal Metastases
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This study tests a drug called Trastuzumab Rezetecan for cancer that has spread to the fluid and lining around the brain and spine.
Read our full plain-language summary
What the trial team says
This phase II clinical study enrolls patients with leptomeningeal metastases from solid tumors. Participants will receive intrathecal and systemic administration of Trastuzumab Rezetecan. The study aims to obtain clinical evidence about the efficacy and safety of this antibody-drug conjugate (ADC) given via intrathecal plus systemic routes. It hopes to offer a new treatment option for these patients with hard-to-manage disease and provide scientific support for optimizing treatment strategies for solid tumor patients with leptomeningeal metastases.
Key facts
- Registry number
- NCT07833657
- Stage of testing
- Phase 2
- Conditions studied
- Leptomeningeal Metastases, Solid Tumors
Where it is running
This trial lists 1 site.
-
Qinghai
- Affiliated Hospital of Qinghai University (Xining)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.